Multiple endogenous enzymes utilizing CDP as a metabolic substrate

Multiple endogenous enzymes utilizing CDP as a metabolic substrate refers to the collective group of enzymes involved in the cytidine diphosphate (CDP) metabolic pathways, particularly the Kennedy pathway for phospholipid biosynthesis (Kennedy & Weiss, 1956, Journal of Biological Chemistry). This group includes key enzymes such as choline-phosphate cytidylyltransferase (PCYT1A) and diacylglycerol cholinephosphotransferase (CHPT1), which utilize CDP-choline to produce phosphatidylcholine, the primary structural phospholipid in neuronal membranes (Grieb, 2014, CNS Drugs). These enzymes are essential for maintaining cellular membrane integrity, supporting mitochondrial function, and facilitating the synthesis of the neurotransmitter acetylcholine. The pharmacological relevance of this group is primarily linked to the drug citicoline (CDP-choline), which serves as an exogenous substrate to boost these metabolic processes in the brain (DrugBank DB01215). By enhancing the activity of these enzymes, citicoline provides neuroprotective effects and supports recovery in patients with ischemic stroke, traumatic brain injury, and various forms of cognitive decline. This target is a functional classification used to describe the multi-step metabolic impact of CDP-related therapeutics rather than a single molecular binding site.

Other names

CDP-utilizing enzymesKennedy pathway enzymesCytidine diphosphate metabolic enzymesPhospholipid biosynthetic enzymes

Acts as a metabolic intermediate that provides cytidine and choline for the de novo synthesis of phosphatidylcholine and increases acetylcholine levels.